Immune Modulation in Heart Failure: the Promise of Novel Biologics

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2018 Mar 16

PMID 29541873

Citations 12

Authors

Paulino Alvarez

Alexandros Briasoulis

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Immune system activation plays a central role in heart failure progression. Large-scale immune modulatory clinical trials targeting tumor necrosis factor-α and broad spectrum immune modulation have been negative. The objective of this review is to highlight past, present, and what is in the horizon for the immunomodulation in heart failure with a focus of biologics.

Recent Findings: Strategies targeting interleukin-1 pathway are currently undergoing clinical evaluation and data from pilot studies are promising. The potential of cell therapy for immune modulation is increasingly recognized in clinical trials. Strategies targeting anti-cardiac antibodies such as immunoadsorption and intravenous immunoglobulin have been used in clinical practice with positive outcomes but large pragmatic clinical trials are lacking. The use of an aptamer to block anti-cardiac antibodies is undergoing phase 1 clinical evaluation. Promising targets include inflammasomes, toll-like receptors, chemokines, natural killer cells, and macrophages. Large-scale immune modulatory clinical trials have been negative. Nevertheless, the experience gained from them along with increasing understanding of molecular mechanisms of immune pathophysiology in heart failure is leading to rapid recognition of new therapeutic targets and approaches.

Citing Articles

Exploring the effects and mechanisms of Guizhigancao Decoction on heart failure using an integrated approach based on experimental support and network pharmacology strategy.

Qu J, Wang J, Zheng B, Jiang X, Liu J, Chen J J Tradit Complement Med. 2023; 13(5):454-464.

PMID: 37693095 PMC: 10491989. DOI: 10.1016/j.jtcme.2023.03.010.

New factors in heart failure pathophysiology: Immunity cells release of extracellular vesicles.

Vilella-Figuerola A, Padro T, Roig E, Mirabet S, Badimon L Front Cardiovasc Med. 2022; 9:939625.

PMID: 36407432 PMC: 9669903. DOI: 10.3389/fcvm.2022.939625.

The relationship of α-hydroxybutyrate dehydrogenase with 1-year outcomes in patients with intracerebral hemorrhage: A retrospective study.

Limin Z, Alsamani R, Jianwei W, Yijun S, Dan W, Yuehong S Front Neurol. 2022; 13:906249.

PMID: 36330431 PMC: 9623007. DOI: 10.3389/fneur.2022.906249.

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy.

Morfino P, Aimo A, Castiglione V, Galvez-Monton C, Emdin M, Bayes-Genis A Heart Fail Rev. 2022; 28(2):555-569.

PMID: 36221014 PMC: 9553301. DOI: 10.1007/s10741-022-10279-x.

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.

Ceelen D, Voors A, Tromp J, Van Veldhuisen D, Dickstein K, de Boer R Eur J Heart Fail. 2022; 24(2):308-320.

PMID: 34989084 PMC: 9302623. DOI: 10.1002/ejhf.2424.

References

Dhondup Y, Sjaastad I, Scott H, Sandanger O, Zhang L, Haugstad S . Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice. PLoS One. 2015; 10(10):e0139715. PMC: 4604200. DOI: 10.1371/journal.pone.0139715. View

Haberland A, Holtzhauer M, Schlichtiger A, Bartel S, Schimke I, Muller J . Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol. 2016; 789:37-45. DOI: 10.1016/j.ejphar.2016.06.061. View

Topkara V, Chambers K, Yang K, Tzeng H, Evans S, Weinheimer C . Functional significance of the discordance between transcriptional profile and left ventricular structure/function during reverse remodeling. JCI Insight. 2016; 1(4):e86038. PMC: 4855517. DOI: 10.1172/jci.insight.86038. View

Sager H, Kessler T, Schunkert H . Monocytes and macrophages in cardiac injury and repair. J Thorac Dis. 2017; 9(Suppl 1):S30-S35. PMC: 5383556. DOI: 10.21037/jtd.2016.11.17. View

Val-Blasco A, Piedras M, Ruiz-Hurtado G, Suarez N, Prieto P, Gonzalez-Ramos S . Role of NOD1 in Heart Failure Progression via Regulation of Ca Handling. J Am Coll Cardiol. 2017; 69(4):423-433. DOI: 10.1016/j.jacc.2016.10.073. View

Wang L, Li Y, Zhang C, Cui W, Wang X, Xia Y . Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res. 2013; 101(3):383-92. DOI: 10.1093/cvr/cvt258. View

Sakata Y, Dong J, Vallejo J, Huang C, Scott Baker J, Tracey K . Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006; 292(1):H503-9. DOI: 10.1152/ajpheart.00642.2006. View

Mann D, McMurray J, Packer M, Swedberg K, Borer J, Colucci W . Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109(13):1594-602. DOI: 10.1161/01.CIR.0000124490.27666.B2. View

Bansal S, Ismahil M, Goel M, Patel B, Hamid T, Rokosh G . Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure. Circ Heart Fail. 2017; 10(3):e003688. PMC: 5331621. DOI: 10.1161/CIRCHEARTFAILURE.116.003688. View

10.

Naftali-Shani N, Levin-Kotler L, Palevski D, Amit U, Kain D, Landa N . Left Ventricular Dysfunction Switches Mesenchymal Stromal Cells Toward an Inflammatory Phenotype and Impairs Their Reparative Properties Via Toll-Like Receptor-4. Circulation. 2017; 135(23):2271-2287. DOI: 10.1161/CIRCULATIONAHA.116.023527. View

11.

Clark D, Cleman M, Pfau S, Rollins S, Ramahi T, Mayer C . Serum complement activation in congestive heart failure. Am Heart J. 2001; 141(4):684-90. DOI: 10.1067/mhj.2001.113758. View

12.

Yoshikawa T, Baba A, Akaishi M, Wakabayashi Y, Monkawa T, Kitakaze M . Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. J Clin Apher. 2016; 31(6):535-544. PMC: 5123585. DOI: 10.1002/jca.21446. View

13.

Levine B, Kalman J, Mayer L, Fillit H, Packer M . Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323(4):236-41. DOI: 10.1056/NEJM199007263230405. View

14.

Frantz S, Kobzik L, Kim Y, Fukazawa R, Medzhitov R, Lee R . Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999; 104(3):271-80. PMC: 408420. DOI: 10.1172/JCI6709. View

15.

deFilippi C, Christenson R . Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle. JACC Heart Fail. 2015; 3(3):253-6. DOI: 10.1016/j.jchf.2014.12.009. View

16.

Torre-Amione G, Kapadia S, Lee J, Durand J, Bies R, Young J . Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996; 93(4):704-11. DOI: 10.1161/01.cir.93.4.704. View

17.

Okamoto N, Noma T, Ishihara Y, Miyauchi Y, Takabatake W, Oomizu S . Prognostic value of circulating regulatory T cells for worsening heart failure in heart failure patients with reduced ejection fraction. Int Heart J. 2014; 55(3):271-7. DOI: 10.1536/ihj.13-343. View

18.

Nahrendorf M, Swirski F . Monocyte and macrophage heterogeneity in the heart. Circ Res. 2013; 112(12):1624-33. PMC: 3753681. DOI: 10.1161/CIRCRESAHA.113.300890. View

19.

Ma Y, Chilton R, Lindsey M . Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension. 2012; 59(5):908-10. PMC: 3996900. DOI: 10.1161/HYPERTENSIONAHA.111.186494. View

20.

Torre-Amione G, Sestier F, Radovancevic B, Young J . Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol. 2004; 44(6):1181-6. DOI: 10.1016/j.jacc.2004.06.047. View